Siludi Pharmaceuticals (01244) Announces Favourable Arbitration: Full Win, SELLAS Continues to Promote the Development and Commercialization of 3D189 in Greater China

Zhitong Finance App learned that 3D Medicines Inc. (01244) issued an insider information notice disclosing that the arbitration case involving the company and SELLAS Life Sciences Group, Inc. (hereinafter referred to as “SELLAS”) has reached a significant positive ruling. The arbitration was fully adjudicated by the Hong Kong International Arbitration Centre, which handed down the final ruling after hearing by a sole arbitrator.

The sole arbitrator made a final ruling, completely rejecting all arbitration claims brought by SELLAS; at the same time, it was determined that SELLAS was responsible for expenses relating to this arbitration, totaling HK$7,983,004.42. SELLAS is required to pay the above amount in full within 14 days from the date the ruling is issued (that is, on or before August 7, 2026); if the arrears are not paid in full and on time, the unpaid amount will be charged overdue interest at an annual interest rate of 8%.

Siludi Pharmaceutical emphasized that this arbitration ruling does not affect the execution of the license agreement between the parties. The company will continue to promote the development and commercialization of 3D189 (WT1 tumor vaccine) in the Greater China region in strict accordance with the licensing agreement between the two parties.

3D189 is a therapeutic tumor vaccine targeting WT1 and is currently undergoing global multi-center phase III clinical trials. According to SELLAS's latest report, the total number of study cases is currently 78. SELLAS remains blind to all efficacy and survival data results. After 80 deaths have occurred, a final analysis will be triggered. At that time, the potential of GPS to meet the treatment needs of AML patients will be further verified.

3D189 lays out a variety of indications and has broad clinical application prospects. The arbitration fully won the lawsuit, cleared up the uncertainty caused by the cooperation dispute, and ensured the steady progress of the company's pipeline development plan.

The arbitration results fully protected the company's legitimate rights and interests. The company will continue to focus on innovative pipeline development and commercialization, steadily promote the construction of cutting-edge platforms such as the commercial operation of Enveda®, RDC nuclear drugs, mRNA-LNP tumor vaccines, and in vivo CAR, and continue to provide patients with high-quality innovative treatment solutions.